DESCRIPTION
Now in its 12th year, this two‐day symposium has been planned for the providers who care for patients with rheumatic disease. Given the wide variety of rheumatologic disorders, and an ever‐increasing number of diagnostic procedures and treatment options, it is necessary to provide clinicians with information about strategies for the early diagnosis of these conditions, novel state‐of‐the‐art diagnostic tools, and opportunities to utilize the most effective treatments to ensure optimal patient outcomes.
TARGET AUDIENCE
This activity is intended for rheumatologists, internists, gerontologists, orthopedic surgeons, nurses and other allied health professionals involved in the care of patients with rheumatic diseases.
OBJECTIVES
After attending this activity, the participant will demonstrate the ability to:
- Discuss treatment strategies in lupus.
- Discuss safety consideration with biologic agents in the treatment of rheumatic disease.
- Discuss current treatment in the management of the pediatric patient with rheumatic disease.
- Identify advances in diagnosis and treatment of osteoporosis in special populations.
- Appraise current management approaches in the diagnosis and treatment of psoriatic arthritis and enthesitis.
- Recognize soft tissue manifestations associated with rheumatic diseases.
- Outline management of chronic pain.
POLICY ON SPEAKER AND PROVIDER DISCLOSURE
It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
NOTICE ABOUT OFF‐LABEL USE PRESENTATIONS
The Johns Hopkins University School of Medicine/12th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases may include presentations on drugs or devices, or use of drugs or devices that have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.
The Johns Hopkins University School of Medicine is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off‐label uses, does not imply an endorsement by Johns Hopkins of the uses, products, or techniques presented.
AMERICANS WITH DISABILITIES ACT
The Johns Hopkins University School of Medicine fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.
COPYRIGHT INFORMATION
All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.
WHAT YOU SHOULD KNOW ABOUT GIFTS TO PHYSICIANS FROM INDUSTRY
Gift giving from the pharmaceutical, device and medical equipment industries to physicians has long been a customary practice. But when gift giving is not practiced within established ethical boundaries, the perception of conflict of interest is raised. All physicians and physicians in training should adhere to the AMA Code of Medical Ethics, Opinion 8.061, “Gifts to Physicians from Industry” which can be found under the AMA Code of Medical Ethics at www.ama‐assn.org/go/ethicalgifts.
Johns Hopkins faculty, staff, employees, students, and trainees must adhere to the more restrictive Johns Hopkins Medicine Policy on Interaction with Industry that can be found on HopkinsMedicine.org by clicking Research > For Our Researchers > Research Affairs Offices > Office of Policy Coordination > Policy on Interaction with Industry or directly through this link http://www.hopkinsmedicine.org/Research/OPC/Policy_Industry_Interaction.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Speakers are required to disclose only
those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:
| Speakers Name and Lecture Titles | Relationships |
| Clifton O. Bingham, III, MD | |
| 16 Years of Biologics: Where are We Now? | Consultant/Advisor: Abbvie; Amgen; Bristol‐Myers Squibb; Flexion; Genentech/Roche; Janssen; Lilly; Macrogenics; Mesoblast; Pfizer; Regeneron/Sanofi; UCB Grant/Research Funding: Janssen; Pfizer |
| Inflammatory Arthritis – Difficult Cases | Consultant/Advisor: Abbvie; Amgen; Bristol‐Myers Squibb; Flexion; Genentech/Roche; Janssen; Lilly; Macrogenics; Mesoblast; Pfizer; Regeneron/Sanofi; UCB Grant/Research Funding: Janssen; Pfizer |
| Robert Brodsky, MD | |
| Anti‐Phospholipid Syndrome and Complement | Consultant/Advisor: Achillion; Alexion Grant/Research Funding: Alexion |
| Lisa Christopher‐Stine, MD, MPH | |
| Advances in Myositis | Consultant/Advisor: Mallinckrodt; Medimmune (AstraZeneca); Novartis and Optioncare Patent Royalty/Intellectual Property Rights: Inova Diagnostics |
| Ana‐Maria Orbai, MD | |
| Updates on Psoriatic Arthritis and Enthesitis | Consultant/Advisor: Janssen Grant/Research Funding: Celgene; Horizon, Eli‐Lilly; Janssen |
| Lunch and Meet the Professor Session | Consultant/Advisor: Janssen Grant/Research Funding: Celgene; Horizon, Eli‐Lilly; Janssen |
| Antony Rosen, MD | |
| Management of Chronic Pain | Patent Royalty/Intellectual Property Rights: Inova Diagnostics |
| Kevin L. Winthrop, MD, MPH | |
| Safety Considerations with Biologic Therapies | Consultant/Advisor: AbbVie; Bristol‐Myers Squibb; Galapagos; Lilly; Pfizer and UCB Grant/Research Funding: Bristol‐Myers Squibb and Pfizer |
No other speaker has indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
| Planners Name | Relationships |
| Clifton O. Bingham, III, MD | Consultant: AbbVie; Amgen; BMS; Genentech/Roche; Janssen; Lilly; Macrogenics; Mesoblast; Pfizer; Regeneron/Sanofi and UCB Principal Investigator: AbbVie; Amgen; BMS; Genentech/Roche; Janssen; Lilly; Macrogenics; Mesoblast; Pfizer; Regeneron/Sanofi and UCB |
No other planner has indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
| Name and Lecture Titles | Product |
| Laura Hummers, MD, ScM | |
| Management of Raynaud’s | Felodipine, amlodipine, nifedipine, losartine, sildenafil, tadalafil, bosentan, macintentan, treprostenil, epoprostenil, epoprostenol, nitroglycerin, fluoxetine, iloprost, botulinum toxin |
| Lisa Christopher‐Stine, MD, MPH | |
| Advances in Myositis | All treatments discussed for myosistis aside from prednisone and Achthar are off‐label and not FDA approved. |
All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.
DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This live-online activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
ACKNOWLEDGEMENT
We wish to acknowledge the following companies that have pledged an educational grant in support of this activity. Please note that the commercial support received is solely for the educational component of the activity and will not be used to provide food and beverage
- Amgen, Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- Pfizer, Inc.
